At the time of writing, Vir Biotechnology Inc [VIR] stock is trading at $8.07, down -1.82%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The VIR shares have lost -0.49% over the last week, with a monthly amount drifted -16.76%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vir Biotechnology Inc [NASDAQ: VIR] stock has seen the most recent analyst activity on January 29, 2024, when JP Morgan downgraded its rating to a Neutral and also revised its price target to $9 from $23. Previously, BofA Securities downgraded its rating to Neutral on September 08, 2023, and dropped its price target to $14. On March 06, 2023, upgrade upgraded it’s rating to Overweight and revised its price target to $34 on the stock. Goldman upgraded its rating to a Buy and increased its price target to $53 on February 21, 2023. Morgan Stanley upgraded its rating to a Equal-Weight and raised its price target to $30 on January 27, 2023. SVB Leerink started tracking with a Outperform rating for this stock on September 14, 2022, and assigned it a price target of $40. In a note dated September 09, 2022, Morgan Stanley initiated an Underweight rating and provided a target price of $15 on this stock.
For the past year, the stock price of Vir Biotechnology Inc fluctuated between $6.56 and $14.45. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Vir Biotechnology Inc [NASDAQ: VIR] shares were valued at $8.07 at the most recent close of the market. An investor can expect a potential return of 147.83% based on the average VIR price forecast.
Analyzing the VIR fundamentals
According to Vir Biotechnology Inc [NASDAQ:VIR], the company’s sales were 74.20M for trailing twelve months, which represents an -26.29% plunge. Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at -7.08%, Pretax Profit Margin comes in at -7.16%, and Net Profit Margin reading is -7.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -0.39 and Total Capital is -0.4. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.93 points at the first support level, and at 7.80 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.26, and for the 2nd resistance point, it is at 8.45.
Ratios To Look Out For
It is important to note that Vir Biotechnology Inc [NASDAQ:VIR] has a current ratio of 8.71. In addition, the Quick Ratio stands at 8.71 and the Cash Ratio stands at 1.86. Considering the valuation of this stock, the price to sales ratio is 14.92, the price to book ratio is 0.96.
Transactions by insiders
Recent insider trading involved de Verneuil Vanina, EVP and General Counsel, that happened on Feb 26 ’25 when 7373.0 shares were sold. Officer, VANINA DE VERNEUIL completed a deal on Feb 26 ’25 to buy 7373.0 shares. Meanwhile, Director SCANGOS GEORGE A sold 10056.0 shares on Feb 24 ’25.
